BCRX (biocryst.com) Market Value to Book Value Ratio

Official company branding of BioCryst Pharmaceuticals, Inc. (BCRX)

The visualization of the BioCryst (BCRX) market price on the GURU.Markets platform demonstrates the dynamics of a company that delegates drug production and testing to third-party contractors to optimize costs. The current figure stands at -4.44, while the financial balance remains stable, covering all business requirements. The high level of professionalism among top management guarantees robust protection of intellectual property and a successful transition to the sales stage.

BCRX BioCryst Corp: Market Value to Book Value in the range 07/04/2022 - 10/27/2026
Original product of BioCryst Pharmaceuticals Inc

Portfolio managers evaluate the BioCryst (BCRX) operating model through the price-to-book ratio, which allows them to compare the current quote with the company's actual capital. By analyzing the extent to which market capitalization exceeds book value, investors can see how the expansion costs of Orladeyo impact the valuation, confirming the company's resilience to liquidity risks while maintaining growth potential.

Main competitors

Market Cap to Net Assets Ratio argenx SE|BNTX (biontech.de) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|grifols.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Adaptive Biotechnologies Corporation (ADPT)|CLDX: Market Value to Book Value|AUPH (Aurinia Pharma) - Market Value to Book Value Ratio|Vera Corp (VERA) - Market Cap to Net Assets Ratio|DNTH (Dianthus Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pharvaris.com (PHVS)|AbCellera Bio (ABCL) - Market Cap to Net Assets Ratio|Market Value to Book Value Tourmaline Bio Inc (TRML)|Market Capitalization to Book Value Ratio PGEN|Pharming Corp - Market Capitalization to Book Value|NKTR: Market Value to Book Value Ratio|UPB: Market Cap to Net Assets Ratio|ZBIO (Zenas Biopharma) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Immunome Inc|GOSS (Gossamer Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio KALV|Market Value to Book Value Ratio Septerna Inc SEPN|Capitalization to Book Value Ratio pieris.com (PVLA)|SVRA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Rigel Pharma RIGL|ANAB - Market Capitalization to Book Value Ratio|ATXS - Market Value to Book Value Ratio|enGene Holdings Inc. - Market Capitalization to Book Value Ratio|RAPT (rapt.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio JBIO (Aerovate Therapeutics, Inc.)|Market-to-Book Ratio Aclaris Therapeutics Inc.|Market Capitalization to Book Value Ratio KYTX (Kyverna)|Market Cap to Net Assets Ratio TLSA (Tiziana Life Sciences, Ltd.)|Market Value to Book Value Ratio Cabaletta Bio, Inc.|VTYX - Market Value to Book Value|THTX (Theratechnologies) - Market Cap to Net Assets Ratio|AVTX: Market-to-Book Ratio|Eledon - Market Value to Book Value Ratio|Market Capitalization to Book Value Agenus, Inc|Climb Bio Inc (CLYM) - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple zurabio.com|Market Capitalization to Book Value Ratio aTyr Pharma (ATYR)|Market Value to Book Value Ratio adagene.com (ADAG)|Ikena Oncology - Market Capitalization to Book Value Ratio|Shattuck Labs Inc - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Equillium Bio (EQ)|Connect Biopharma (CNTB) - Market Value to Book Value|Market Cap to Net Assets Ratio immunic-therapeutics.com|ATRA (Atara Bio) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio InflaRx NV IFRX|Market Capitalization to Net Assets X4 Pharmaceuticals, Inc|Adicet Bio (ACET) - Market Capitalization to Book Value Ratio|Market Value to Book Value celularity.com (CELU)|Market Capitalization to Book Value Ratio INMB (INmune Bio)|Barinthus Biotherapeutics PLC - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Kezar Life Sciences, Inc (KZR)|SABS: Market Value to Book Value|AKTX (Akari Therapeutics) - Market Value to Book Value Ratio|Enlivex Therapeutics Ltd. (ENLV) - Market Cap to Net Assets Ratio|QTTB (Q32 Bio Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio GeoVax Labs (GOVX)|Edesa (EDSA) - Market Cap to Net Assets Ratio|Market Value to Book Value iBio Corporation (IBIO)|Market Capitalization to Book Value Ratio CARM|xtlbio.com - Market Capitalization to Book Value|BOLT: Market Value to Book Value Ratio|HCWB: Market Cap to Net Assets Ratio|APVO (aptevotherapeutics.com) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio aimimmuno.com|ADTX (Aditxt Inc.) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio GRI|Market Value to Book Value Ratio XORTX Therapeutics XRTX|Capitalization to Book Value Ratio Vyome Holdings Inc. (HIND)|REVB: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Indaptus Corp INDP|SCNI - Market Capitalization to Book Value Ratio|CALI - Market Value to Book Value Ratio|affimed.com - Market Capitalization to Book Value Ratio|ALLK (Allakos) - Market Capitalization to Book Value|Market Value to Book Value Ratio HOOK (HOOKIPA Pharma, Inc.)|Market-to-Book Ratio IGM Bio|Market Capitalization to Book Value Ratio ITOS (iTeos Therapeutics)|Market Cap to Net Assets Ratio OCEA (oceanbiomedical.com)|Market Value to Book Value Ratio TC BioPharm|THRD - Market Value to Book Value